| 刘华美,刘亚佳.不同胰岛素给药方式对PCOS合并GDM患者血糖控制及妊娠结局的影响.[J].中南医学科学杂志.,2026,(1):67-70. |
| 不同胰岛素给药方式对PCOS合并GDM患者血糖控制及妊娠结局的影响 |
| Impact of different insulin administration methods on blood glucose control and pregnancy outcomes in patients with PCOS complicated by GDM |
| 投稿时间：2025-04-08 修订日期：2025-11-18 |
| DOI：10.15972/j.cnki.43-1509/r.2026.01.015 |
| 中文关键词: 多囊卵巢综合征 妊娠期糖尿病 胰岛素泵 血糖控制 妊娠结局 |
| 英文关键词:polycystic ovary syndrome gestational diabetes mellitus insulin pump blood glucose control pregnancy outcome |
| 基金项目:河北省医学科学研究课题计划项目(20210207) 作者简介:刘华美,主治医师,研究方向为产科疾病的诊治,E-mail为liuhuamei1982@163.com。通信作者刘亚佳,主治医师,研究方向为产科疾病的诊治,E-mail为liuyajia071433@163.com。 |
|
| 摘要点击次数: 0 |
| 全文下载次数: 0 |
| 中文摘要: |
| 目的探讨不同胰岛素给药方式对多囊卵巢综合征(PCOS)合并妊娠期糖尿病(GDM)患者血糖控制及妊娠结局的影响。 方法回顾性选择接受胰岛素治疗的GDM合并PCOS孕妇,依据初始胰岛素给药方式分为持续皮下胰岛素输注(CSII)组、多次皮下注射(MDI)组和基础餐时组。比较各组糖化血红蛋白、血糖达标周期及围产期并发症发生情况,采用多因素Logistic回归分析巨大儿发生的影响因素。 结果治疗后,各组上述血糖指标均较同组治疗前显著改善,血糖达标时间显著缩短(P＜0.05),且CSII组血糖指标改善程度及达标效率均优于MDI组和基础餐时组(P＜0.05)。CSII组巨大儿、新生儿低血糖及剖宫产发生率均低于其他两组(P＜0.05)。多因素Logistic回归分析显示,胰岛素治疗方案是巨大儿发生的独立影响因素,CSII为显著保护因素(P＜0.05)。 结论CSII能有效优化PCOS-GDM患者糖代谢稳态,降低妊娠不良结局风险,具有临床推广价值。 |
| 英文摘要: |
| AimTo explore the effects of different insulin administration methods on blood glucose control and pregnancy outcomes in patients with polycystic ovary syndrome (PCOS) complicated by gestational diabetes mellitus (GDM). MethodsPregnant women with GDM and PCOS who received insulin therapy were retrospectively selected. They were divided into three groups based on the initial insulin administration methods, namely continuous subcutaneous insulin infusion (CSII) group, multiple daily injections (MDI) group, and basal-bolus group, respectively. Glycated hemoglobin, time to achieve blood glucose targets, and incidence of perinatal complications were compared among the groups. Multivariate Logistic regression was used to analyze influencing factors for macrosomia. ResultsAfter treatment, all three groups showed significant improvements in these glucose metrics and a shorter time to achieve target glucose levels (P＜0.05). The CSII group demonstrated superior improvements in glucose control and efficiency in reaching targets compared with the MDI and basal-bolus groups (P＜0.05). The incidences of macrosomia, neonatal hypoglycemia, and cesarean section were lower in the CSII group than those in the other two groups (P＜0.05). Multivariate Logistic regression analysis indicated that the insulin treatment regimen was an independent influencing factor for macrosomia, with CSII serving as a significant protective factor (P＜0.05). ConclusionCSII effectively optimizes glucose metabolic homeostasis in PCOS-GDM patients, reduces the risk of adverse pregnancy outcomes, and holds clinical promotion value. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|